Journal Club Naudia N. Lauder, M.D. Evan J. Lipson, M.D. David T. Majure, M.D., M.P.H.

Slides:



Advertisements
Similar presentations
THE IMPORTANCE OF PUBLISHING NEGATIVE FINDINGS Rolofylline, an Adenosine A1 – Receptor Antagonist, in Acute Heart Failure Barry M. Massie et al The New.
Advertisements

Horng H Chen MD on behalf of the NHLBI Heart Failure Clinical Research Network Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF):
Journal Club Rakesh Latchamsetty October 5, 2007.
Clinical Trial Results. org Clopidogrel Use and Long-term Clinical Outcomes After Drug-Eluting Stent Implantation Eric Eisenstein, DBA; Kevin Anstrom,
Basic Design Consideration. Previous Lecture Definition of a clinical trial The drug development process How different aspects of the effects of a drug.
天 津 医 科 大 学天 津 医 科 大 学 Clinical trail. 天 津 医 科 大 学天 津 医 科 大 学 1.Historical Background 1537: Treatment of battle wounds: 1741: Treatment of Scurvy 1948:
Study by: Granger et al. NEJM, September 2011,Vol No. 11 Presented by: Amelia Crawford PA-S2 Apixaban versus Warfarin in Patients with Atrial Fibrillation.
Topic 6: Introduction to Hypothesis Testing
Anticoagulation in Acute Ischemic Stroke. TPA: Tissue Plasminogen Activator 1995: NINDS study of TPA administration Design: randomized, double blind placebo-controlled.
“Acute Coronary Syndromes: Trials & Tribulations" Will Southern, M.D., M.S. Director of Hospitalist Services Associate Medical Director Weiler Division.
Can we prevent myocardial and renal revascularization injury? Preventive effect of trimetazidine MR on myocardial and renal injury in diabetic patients.
Cohort Studies Hanna E. Bloomfield, MD, MPH Professor of Medicine Associate Chief of Staff, Research Minneapolis VA Medical Center.
Clinical Trial Results. org Pexelizumab for Acute ST-Elevation Myocardial Infarction in Patients Undergoing Primary Percutaneous Coronary Intervention.
Randomized Angioplasty Beta Blocker Intracoronary Trial II (RABBIT II) Presented at The American Heart Association Scientific Session 2006 Presented by.
A Randomized Trial of IV Ibuprofen and Morphine Combination Therapy in Patients Presenting with Renal Colic Calliandra Hintzen, BS, Dan Quan, DO Maricopa.
Early high-dose Rosuvastatin for Contrast-Induced Nephropathy Prevention in Acute Coronary Syndrome The PRATO-ACS (Protective effect of Rosuvastatin and.
CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.
A Prospective Randomized Trial of Furosemide-Induced High-Volume Diuresis with Matched Hydration Using a Dedicated Device to Prevent Contrast Nephropathy.
Sarah Struthers, MD March 19, 2015
C.R.E.D.O. C lopidogrel for the R eduction of E vents D uring O bservation Multicenter Multinational (USA, Canada) Prospective Randomized Double Blind.
Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study) Lambers Heerspink,
ARMYDA-CIN Trial [Atorvastatin for Reduction of Myocardial Damage during Angioplasty–Contrast-Induced Nephropathy]
Effects of PG , a Matrix Metalloproteinase Inhibitor to Prevent Left Ventricular Remodeling After Acute Myocardial Infarction Effects of PG ,
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
High Versus Standard Clopidogrel Maintenance Dose After Percutaneous Coronary Intervention: Effects on Platelet Inhibition, Endothelial Function and Inflammation.
Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty Study (ARMYDA-2) Trial ARMYDA-2 Trial Presented at The American College of Cardiology.
1 SIROLIMUS-ELUTING STENTS FOR IN-STENT RESTENOSIS TREATMENT IN 278 UNSELECTED PATIENTS: INSIGHTS ON LONG-TERM OUTCOMES FROM A LARGE TWO-CENTER REGISTRY.
Randomized Trial of Ea rly S urgery Versus Conventional Treatment for Infective E ndocarditis (EASE) Duk-Hyun Kang, MD, PhD on behalf of The EASE Trial.
ARMYDA-4 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study Prospective, multicenter, randomized, double blind trial investigating.
HORIZONS AMI Trial H armonizing O utcomes with R evascular IZ ati ON and S tents In A cute M ycoardial I nfarction H armonizing O utcomes with R evascular.
Athens Cardiology Update CADILLAC Study Blood Transfusion after Myocardial Infarction: Friend, Foe or double-edged Sword? Georgios I. Papaioannou,
Which Early ST-Elevation Myocardial Infarction Therapy (WEST) Trial Paul W. Armstrong, WEST Steering Committee Published in The European Heart Journal.
BIOE 301 Lecture Seventeen. Progression of Heart Disease High Blood Pressure High Cholesterol Levels Atherosclerosis Ischemia Heart Attack Heart Failure.
Occluded Artery Trial (OAT) Presented at The American Heart Association Scientific Session 2006 Presented by Dr. Judith S. Hochman OAT Trial.
The Additive Value of Tirofiban Administered With the High-Dose Bolus in the Prevention of Ischemic Complications During High-Risk Coronary Angioplasty.
Greg Gaines PA-S A RANDOMIZED TRIAL OF GLUTAMINE AND ANTIOXIDANTS IN CRITICALLY ILL PATIENTS.
Conclusions. Conclusions -In patients undergoing primary angioplasty, prophylactic treatment with N-acetylcysteine seems to reduce the rate of contrast-medium.
DOSE-AHF Diuretic Optimization Strategies Evaluation in Acute Heart Failure Duke Heart Failure Research Pager:
Heart rate in heart failure: Heart rate in heart failure: risk marker or risk factor? A subanalysis of the SHIFT trial on behalf of the Investigators M.
Paclitaxel Eluting Stent Versus Conventional Stent in ST-segment Elevation Myocardial Infarction (PASSION) Trial Presented at The American College of Cardiology.
A Review of – Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Ted Williams Pharm D Candidate Monday Lab.
Hexabrix Key Clinical Review Liss, 2006 Mid-Year Sales Meeting Bloomington, IN July 13 th – 17 th.
¨ 8 European countries, 48 centres Stent implantation Double-blind randomisation n = 1005 Clopidogrel 300mg od Aspirin 325mg od Clopidogrel 75mg od Aspirin.
ARNO TRIAL (Antithrombotic Regimens aNd Outcome) A RANDOMIZED TRIAL COMPARING BIVALIRUDIN WITH UNFRACTIONED HEPARIN IN PATIENTS UNDERGOING ELECTIVE PCI.
ADMIRALADMIRAL Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long term follow-up ADMIRAL Study ADMIRAL.
GUSTO IV ACS: Trial Design Abciximab versus placebo in very high-risk patients with non-ST elevation acute coronary syndromes: – ST  > 0.5 mm or – elevated.
FRagmin® and Fast Revascularization during InStablity in Coronary artery disease FRISC II.
VBWG OASIS-6 The Sixth Organization to Assess Strategies in Acute Ischemic Syndromes trial.
ARMYDA-4 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study Prospective, multicenter, randomized, double blind trial investigating.
Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty Study (ARMYDA-2) Trial ARMYDA-2:ARMYDA-2:
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at The American College.
Total Occlusion Study of Canada (TOSCA-2) Trial
Angiotensin converting enzyme inhibitors / angiotensin receptor blockers and contrast induced nephropathy in patients receiving cardiac catheterization:
These slides highlight a presentation at the Late Breaking Trial Session of the American College of Cardiology 52nd Annual Scientific Sessions in Chicago,
The American College of Cardiology Presented by Dr. Adnan Kastrati
Early high-dose Rosuvastatin for
Strategies to Reduce Acute Kidney Injury and Improve Clinical Outcomes After Percutaneous Coronary Intervention: A Subgroup analysis of the Prevention.
Hexabrix Key Clinical Review Mehran, 2009
Glenn N. Levine et al. JACC 2016;68:
The American College of Cardiology Presented by Dr. Maurits T. Dirksen
Atorvastatin for Reduction of Myocardial Damage During Angioplasty
Section D: Clinical trial update: GP IIb/IIIa inhibition
Preventive Angioplasty in Myocardial Infarction Trial
American Heart Association Presented by Dr. Julinda Mehilli
Erasmus MC, Thoraxcenter
DEScover: One-Year Clinical Results
Sirolimus Stent vs. Bare Stent in Acute Myocardial Infarction Trial
TYPHOON Trial Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at.
Section C: Clinical trial update: Oral antiplatelet therapy
Presentation transcript:

Journal Club Naudia N. Lauder, M.D. Evan J. Lipson, M.D. David T. Majure, M.D., M.P.H.

Hx of the J-Club  Sir William Osler established the first formalized journal club at McGill University in Montreal in  The original purpose of Osler's journal club was "for the purchase and distribution of periodicals to which he could ill afford to subscribe.“ 1 1. The ever-reliable Wikipedia…

Rules of J-club 1 st rule of J-Club: Don’t talk about J-club.

Incidentally…  Happy 157 th birthday, Dr. Osler. (a day late)

N-Acetylcysteine and Contrast-Induced Nephropathy in Primary Angioplasty NEJM 354;26 June 29, 2006 Marenzi et al. at the Institute of Cardiology, University of Milan, Italy And now, down to business…

Background  Patients with acute MI undergoing primary angioplasty are at high risk for contrast induced nephropathy.  NAC is a scavenger of oxygen-derived free radicals and causes endothelium-dependent vasodilation.  Approximately a dozen studies on the prophylactic effect of N-acetylcysteine have been published, with contradictory results.

Background  Research question: Can the antioxidant N- acetylcysteine prevent contrast induced nephropathy in patients undergoing primary angioplasty.** **Primary angioplasty vs. elective PCI (e.g. after positive stress echo)

Study population: Over 2 years, all patients admitted to the CCU at Centro Cardiologico Monzino in Milan for STEMI who would then undergo angioplasty Had to present within 12 hours (18 hours in cases of cardiogenic shock) after the onset of symptoms Exclusion criteria were long-term dialysis and known allergy to N-acetylcysteine The study was approved by the ethics committee, and written informed consent was obtained from all patients Let’s walk through it…  Methods

Methods  Eligible patients were randomly assigned to receive standard dose NAC, double dose NAC or placebo. 

Standard dose: 600mg IV bolus NAC before PCI, then 600mg po bid for 48 hours after PCI Double dose: 1200mg IV bolus NAC before PCI, then 1200mg po bid for 48 hours after PCI Placebo

Methods  After intervention, all patients received Normal Saline at 1ml/kg/hr. (or 0.5ml/kg/hr in cases of overt heart failure) for 12 hours.  The use of intraaortic balloon pumps, inotropic drugs, abciximab, beta-blockers, ACE inhibitors and diuretics was left to the discretion of the CCU/Cath cardiologists  Left ventricular function was evaluated by echocardiography in all patients within 24 hours after admission.  Investigators involved in the procedures and those reading echocardiograms were blinded to the treatment randomization.

 Primary end point: occurrence of contrast induced nephropathy, defined as an increase in serum creatinine by ≥25 percent from baseline value within the 72-hour period after PCI.  The major in-hospital clinical events, including death, were recorded. Methods

Methods   The contrast used was iohexol (omnipaque) which is low-osmolar and non-ionic. (versus Visipaque which is iso-osmolar, non-ionic, more expensive, and less damaging to kidneys)   Bare-metal stents (versus drug eluting) were implanted in all patients. Post-stenting antithrombotic treatment consisted of aspirin and either clopidogrel or ticlopidine at standard dosages.   N-acetylcysteine was purchased by the investigators.

Methods  Study was powered assuming a reduction in the average rate of nephropathy by 50 percent in the treatment arm vs. placebo (e.g. from 30 to 15 percent).  100 patients in each group allowed for a statistical power of 80 percent, with a type I error of  80% chance that you will avoid a false null hypothesis.  5% chance of a obtaining a statistically significant result and rejecting the null hypothesis when it is in fact is true.

 Statistical analysis was done as follows:  Clinical characteristics of the three groups: ANOVA for continuous variables, chi-square test or Fisher's exact test for categorical variables.  Time course of creatinine values among the three groups: ANCOVA  Incidence of complications among the three groups: Wald chi-square test with two degrees of freedom and by the Mantel–Haenszel chi-square test for trend.  A P-value of less than 0.05 was considered to indicate statistical significance. Methods